Keryx Wants Auryxia Stock-Drop Suit Reconsidered
Keryx Biopharmaceuticals Inc. has refused to accept a judge's decision that a proposed class action validly alleged that the company misled investors to believe it had mitigated supply chain risks before...To view the full article, register now.
Already a subscriber? Click here to view full article